The estimated Net Worth of Timothy M Sullivan is at least $153 Thousand dollars as of 27 May 2014. Timothy Sullivan owns over 160,599 units of Idera Pharmaceuticals stock worth over $79,771 and over the last 17 years Timothy sold IDRA stock worth over $73,227.
Timothy has made over 3 trades of the Idera Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently Timothy exercised 160,599 units of IDRA stock worth $144,539 on 27 May 2014.
The largest trade Timothy's ever made was exercising 160,599 units of Idera Pharmaceuticals stock on 27 May 2014 worth over $144,539. On average, Timothy trades about 14,053 units every 184 days since 2008. As of 27 May 2014 Timothy still owns at least 185,513 units of Idera Pharmaceuticals stock.
You can see the complete history of Timothy Sullivan stock trades at the bottom of the page.
Timothy's mailing address filed with the SEC is C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro..., and Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: